---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-008131"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:24:07.406751+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical reports Q2 net loss down to $3.0M; CEO Fisher replaced by Frakes

## Summary
- Net loss for fiscal Q2 2023: $3.0M vs $3.8M in prior year; operating expenses decreased 13.4% to $3.2M.
- Cash balance $10.2M as of Sept 30, 2023.
- CEO Charles Fisher replaced by James Frakes (Interim CEO, retains CFO role); Guy Cipriani becomes COO.
- Received DCGI clearance in India for Phase 1 Hemopurifier trial in solid tumors on anti-PD-1 therapy.
- Hemopurifier supply disruption continues; working with FDA for second GNA supplier; new San Diego facility.

## SEC filing metadata
- accession: 0001683168-23-008131
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316823008131/0001683168-23-008131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316823008131/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-008131
- JSON: https://secwatch.observer/filing/0001683168-23-008131.json
- Plain text: https://secwatch.observer/filing/0001683168-23-008131.txt

## Key facts
- Earnings Releases
  AETHLON MEDICAL INC reported financial results for fiscal second quarter ended September 30, 2023.
  - Period: fiscal second quarter ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, Aethlon Medical, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882291/000168316823008131/0001683168-23-008131-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.